BRIEF-Samsara Vision To Initiate A U.S. Pma Supplemental Study Of The Sing Imt™, A New-Generation Technology For Age-Related Macular Degeneration
BRIEF-Samsara Vision To Initiate A U.S. Pma Supplemental Study Of The Sing Imt™, A New-Generation Technology For Age-Related Macular Degeneration
Brief-samsara Vision 将启动一项针对年龄相关性黄斑变性的新一代技术 The Sing Imt™ 的美国 Pma 补充研究
* SAMSARA VISION INC - CONCERTO TRIAL WILL INCLUDE UP TO TWENTY CLINICAL SITES ACROSS UNITED STATESApril 20 (Reuters) - Samsara Vision Inc SMSA.O :
4 月 20 日（路透社）— Samsara Vision Inc SMSA.O：
* SAMSARA VISION TO INITIATE A U.S. PMA SUPPLEMENTAL STUDY OF THE SING IMT™, A NEW-GENERATION TECHNOLOGY FOR AGE-RELATED MACULAR DEGENERATION
* SAMSARA 愿景将启动美国 PMA 对 SING IMT™ 的补充研究，这是一种治疗与年龄相关的黄斑变性的新一代技术
* SAMSARA VISION - ANNOUNCED FDA APPROVAL TO INITIATE U.S.-BASED, PMA SUPPLEMENTAL STUDY
* SAMSARA VISION——宣布美国食品药品管理局批准启动总部位于美国的PMA补充研究
* SAMSARA VISION INC - CONCERTO TRIAL WILL INCLUDE UP TO TWENTY CLINICAL SITES ACROSS UNITED STATES
* SAMSARA VISION INC-CONCERTO 试验将包括美国多达二十个临床研究点
Source text for Eikon: ID:nBw5JsrLja Further company coverage: SMSA.O
Eikon 的来源文本：id: nbw5jsrlja 进一步的公司报道：SMSA.O
资讯热榜
更新时间